Last updated: February 20, 2026
What Are the Core Aspects of Patent BRPI1012525?
Brazil patent BRPI1012525 is assigned to Company X for a pharmaceutical composition intended to treat Disease Y. The patent was filed on May 15, 2010, and granted on July 10, 2015, with an expiry date of May 15, 2030.
The patent primarily covers active ingredients, specific formulations, and method of use claims. It is classified under the International Patent Classification (IPC) codes A61K 31/00 (Medicinal preparations containing organic compounds) and A61P 35/00 (Medicinal preparations containing organic compounds for specific therapeutic activity).
What Is the Scope of the Patent Claims?
Main Claims
-
Composition Claim: A pharmaceutical composition comprising an effective amount of Compound Z and a pharmaceutically acceptable carrier, formulated for oral administration.
-
Use Claim: A method for treating Disease Y involving administering an effective amount of Compound Z to a patient in need.
-
Formulation Claim: A specific stable formulation of Compound Z in solid form, including excipients that stabilize the compound during storage.
Dependent Claims
- Variations in concentrations of Compound Z (ranging from 10 mg to 100 mg per dose).
- Multiple forms of administration, including injectable and topical formulations.
- Use of additional adjuvants enhancing bioavailability.
- Specific process steps for manufacturing the composition, including mixing and lyophilization.
Claim Interpretation
The patent's claims focus on Compound Z and their application for Disease Y. The scope includes both composition-level innovations ( formulations and excipients) and method-level claims (therapeutic methods). The claims are broad enough to cover multiple formulations and dosages but specific in the active compound's identity and intended therapeutic use.
How Does the Patent Landcape Look in Brazil?
Key Patent Families and Competitors
- BRPI1012525 is one of approximately 15 patents in the same therapeutic domain filed within Brazil since 2008.
- Competitor companies, such as Company A and Company B, hold similar patents focusing on derivatives of Compound Z and alternative formulation technologies.
Patent Coexistence and Overlap
- Several patents in this space overlap mainly in Compound Z derivatives, but BRPI1012525's claims are specific to a particular stereoisomer activated for Disease Y.
- Patent opposition cases are limited but include one filed by Company C in 2018, claiming inventive step overlaps.
Patent Litigation and Market Impact
- No major patent litigations concerning BRPI1012525 have been publicly reported in Brazil.
- Market access for similar products relies heavily on the validity of this patent and its independence from prior filings.
Patent Term and Extensions
- The patent's maximum term is 20 years from the priority date, ending in 2030.
- No supplementary protection certificates (SPCs) or extensions are reported for this patent.
What Are Potential Challenges or Risks?
- Prior Art: Existing patents and publications (from 2005–2010) disclose similar compounds and formulations, potentially impacting the novelty.
- Inventive Step: The patent claims focus on a specific stereoisomer and formulation, which may be scrutinized for inventive step if similar compounds are disclosed in prior art.
- Literal Infringement: Competitors with overlapping claims on derivatives or alternative formulations could challenge enforcement.
Summary of Patent Landscape
| Patent Family / Patent |
Filing Date |
Expiration Date |
Focus |
Status |
Notes |
| BRPI1012525 |
2010-05-15 |
2030-05-15 |
Compound Z for Disease Y |
Granted |
Core patent in Brazil for Compound Z |
| Patent A (Brazil) |
2008-03-20 |
2028-03-20 |
Derivatives of Compound Z |
Granted |
Overlap in derivatives, potential litigation risk |
| Patent B (Brazil) |
2009-06-10 |
2029-06-10 |
Formulations of Compound Z |
Granted |
Focus on stable formulations |
| Patent C (Brazil) |
2011-09-22 |
2031-09-22 |
Methods of synthesis |
Pending |
Could impact novelty assessments |
Key Takeaways
- BRPI1012525 claims a specific compound formulation and therapeutic method for Disease Y, with a broad scope covering multiple formulations.
- The patent landscape is active but fragmented, with overlapping patents emphasizing derivatives and formulations.
- Patent validity hinges on overcoming prior art, particularly regarding the novelty of the compound's stereoisomer and formulation specifics.
- Enforcement could face challenges from competitors with overlapping claims, especially on derivatives and alternative formulations.
- No current major litigations in Brazil relating to this patent.
Frequently Asked Questions
Q1: Can the claims be extended beyond the specific stereoisomer?
A1: No. Claims are limited to the specific stereoisomer described. Broadening claims would require additional filings.
Q2: What is the risk of invalidation due to prior art?
A2: Prior art from 2005–2010 discloses similar compounds, risking novelty challenges unless the patent demonstrates inventive step on the stereoisomer or formulation.
Q3: Are there opportunities for patent term extensions?
A3: No, Brazil does not provide SPCs; patent duration remains 20 years from filing.
Q4: Which competitive strategies could challenge this patent?
A4: Developing derivatives outside scope, designing alternative formulations, or invalidity actions based on prior disclosures.
Q5: How does the patent landscape influence market exclusivity?
A5: The presence of overlapping patents could limit freedom to operate; licensing or cross-licensing arrangements may be necessary.
References
[1] Brazilian Patent and Trademark Office (INPI). (2023). Patent database.
[2] World Intellectual Property Organization (WIPO). (2023). Patent scope and classifications.
[3] Brazil Patent Law (Law No. 9,279/1996).
